MedTrace Logo

Safety and Tolerability of Odanacatib (0822-059)

NCT01068262 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2018-08-28

Study results available
· View outcomes & findings →

Summary

This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib

Conditions

Interventions

DRUG

Odanacatib

Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks

DRUG

Comparator: Placebo

Oral Placebo tablet administered once weekly for 4 consecutive weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-08
Primary Completion
2010-04-26
Completion
2010-05-02

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01068262 on ClinicalTrials.gov